Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.62 |
| ▸ | TYMP | P19971 | 8/20 | 0.62 |
| ▸ | NT5E | P21589 | 1/20 | 0.51 |
| ▸ | TRDMT1 | O14717 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18042131 | 0.94 | ADORA1 (0.64) | ADORA1TYMPNT5ETRDMT1 | |
| SCHEMBL15993919 | 0.91 | ADORA1 (0.75) | ADORA1TYMPTRDMT1 | |
| SCHEMBL1068571 | 0.91 | ADORA1 (0.75) | ADORA1TYMPTRDMT1 | |
| SCHEMBL16715145 | 0.91 | ADORA1 (0.75) | ADORA1TYMPTRDMT1 | |
| SCHEMBL8359104 | 0.91 | ADORA1 (0.75) | ADORA1TYMPTRDMT1 | |
| SCHEMBL1068575 | 0.89 | ADORA1 (0.64) | ADORA1TYMPNT5ETRDMT1 | |
| SCHEMBL29799117 | 0.89 | NT5E (0.65) | ADORA1TYMPNT5E | |
| SCHEMBL6394672 | 0.88 | TYMP (0.58) | ADORA1TYMPNT5E | |
| SCHEMBL6394822 | 0.88 | TYMP (0.58) | ADORA1TYMPNT5E | |
| SCHEMBL22930672 | 0.85 | TYMP (0.61) | ADORA1TYMPNT5ETRDMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12269839-B2 | Chiral phosphoramidite auxiliaries and methods of their use | SIRIUS THERAPEUTICS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20230242567-A1 | CHIRAL PHOSPHORAMIDITE AUXILIARIES AND METHODS OF THEIR USE | SIRIUS THERAPEUTICS, INC. | 2023-08-03 | — | — | US | disclosed |
| US-11597744-B2 | Chiral phosphoramidite auxiliaries and methods of their use | SIRIUS THERAPEUTICS, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| US-20200140476-A1 | CHIRAL PHOSPHORAMIDITE AUXILIARIES AND METHODS OF THEIR USE | SIRIUS THERAPEUTICS, INC. | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242567-A1 | CHIRAL PHOSPHORAMIDITE AUXILIARIES AND METHODS OF THEIR USE | PNP, PCNA, NUDT14 | ADORA1 952/4885TYMP 4/4885NT5E 474/4885 |
| US-12269839-B2 | Chiral phosphoramidite auxiliaries and methods of their use | PNP, PCNA, NUDT14 | ADORA1 952/4885TYMP 4/4885NT5E 474/4885 |
| US-11597744-B2 | Chiral phosphoramidite auxiliaries and methods of their use | TYMP, PNP, PCNA | ADORA1 294/4885TYMP 1/4885NT5E 359/4885 |
| US-20200140476-A1 | CHIRAL PHOSPHORAMIDITE AUXILIARIES AND METHODS OF THEIR USE | PNP, PCNA, NUDT14 | ADORA1 952/4885TYMP 4/4885NT5E 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.